The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 14, 2022

Filed:

Aug. 23, 2018
Applicant:

Medicinal Bioconvergence Research Center, Suwon-si, KR;

Inventors:

Sunghoon Kim, Seoul, KR;

Min Chul Park, Seongnam-si, KR;

Peter Charles Goughnour, Suwon-si, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 31/00 (2006.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01); C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
G01N 33/57419 (2013.01); C12Q 1/68 (2013.01); C12Q 1/6886 (2013.01); G01N 33/574 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/9015 (2013.01);
Abstract

The present invention relates to a colorectal cancer diagnostic composition and method for detecting a diagnostic marker, more specifically to a colorectal cancer diagnostic composition comprising one or more mRNAs selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1) of a preparation for measuring protein expression levels thereof, and a method for detecting a marker form a sample obtained from a test subject in order to provide information necessary for diagnosing colorectal cancer. The colorectal cancer diagnostic marker comprising KRS and AIMP1, according to the present invention, has raised expression levels of same in the serum of a colorectal cancer patient in comparison to a normal control group. Therefore, whether colorectal cancer is present can be accurately and rapidly determined by measuring the expression levels of one or more markers selected from the group consisting of KRS and AIMP1.


Find Patent Forward Citations

Loading…